Canadian biotech firm AbCellera Q2 revenue beats estimates
Overview
AbCellera Q2 2025 revenue of $17.1 mln beats analyst expectations, per LSEG data
Net loss narrows to $34.7 mln from $36.9 mln in Q2 2024
Result Drivers
REVENUE GROWTH - Revenue increased to $17.1 mln, driven by higher licensing revenue
STRONG LIQUIDITY - Over $750 mln in available liquidity supports ongoing strategy
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $17.10 mln | $6.12 mln (6 Analysts) |
Q2 Net Income |
| -$34.70 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Abcellera Biologics Inc is $9.00, about 54.2% above its August 6 closing price of $4.12
Press Release: ID:nBw4Sf3WTa
